IDEXX LABORATORIES INC (IDXX) Fundamental Analysis & Valuation
NASDAQ:IDXX • US45168D1046
Current stock price
563 USD
-21.75 (-3.72%)
At close:
563 USD
0 (0%)
After Hours:
This IDXX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. IDXX Profitability Analysis
1.1 Basic Checks
- IDXX had positive earnings in the past year.
- IDXX had a positive operating cash flow in the past year.
- IDXX had positive earnings in each of the past 5 years.
- IDXX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of IDXX (31.62%) is better than 99.47% of its industry peers.
- With an excellent Return On Equity value of 65.99%, IDXX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- The Return On Invested Capital of IDXX (41.85%) is better than 100.00% of its industry peers.
- IDXX had an Average Return On Invested Capital over the past 3 years of 37.64%. This is significantly above the industry average of 9.40%.
- The last Return On Invested Capital (41.85%) for IDXX is above the 3 year average (37.64%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.62% | ||
| ROE | 65.99% | ||
| ROIC | 41.85% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.64%
ROIC(5y)38.05%
1.3 Margins
- The Profit Margin of IDXX (24.62%) is better than 95.74% of its industry peers.
- IDXX's Profit Margin has improved in the last couple of years.
- IDXX has a better Operating Margin (31.60%) than 98.94% of its industry peers.
- In the last couple of years the Operating Margin of IDXX has grown nicely.
- IDXX has a better Gross Margin (61.80%) than 63.83% of its industry peers.
- IDXX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.6% | ||
| PM (TTM) | 24.62% | ||
| GM | 61.8% |
OM growth 3Y5.77%
OM growth 5Y4.3%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
2. IDXX Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IDXX is creating value.
- The number of shares outstanding for IDXX has been reduced compared to 1 year ago.
- IDXX has less shares outstanding than it did 5 years ago.
- IDXX has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 21.39 indicates that IDXX is not in any danger for bankruptcy at the moment.
- The Altman-Z score of IDXX (21.39) is better than 94.15% of its industry peers.
- The Debt to FCF ratio of IDXX is 0.81, which is an excellent value as it means it would take IDXX, only 0.81 years of fcf income to pay off all of its debts.
- IDXX has a Debt to FCF ratio of 0.81. This is amongst the best in the industry. IDXX outperforms 90.43% of its industry peers.
- A Debt/Equity ratio of 0.48 indicates that IDXX is not too dependend on debt financing.
- IDXX has a Debt to Equity ratio (0.48) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 0.81 | ||
| Altman-Z | 21.39 |
ROIC/WACC4.73
WACC8.85%
2.3 Liquidity
- A Current Ratio of 1.23 indicates that IDXX should not have too much problems paying its short term obligations.
- The Current ratio of IDXX (1.23) is worse than 83.51% of its industry peers.
- IDXX has a Quick Ratio of 1.23. This is a bad value and indicates that IDXX is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 0.90, IDXX is doing worse than 82.45% of the companies in the same industry.
- The current and quick ratio evaluation for IDXX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.9 |
3. IDXX Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an nice 16.18% over the past year.
- The Earnings Per Share has been growing by 14.26% on average over the past years. This is quite good.
- The Revenue has grown by 10.42% in the past year. This is quite good.
- IDXX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.72% yearly.
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
3.2 Future
- IDXX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.75% yearly.
- Based on estimates for the next years, IDXX will show a quite strong growth in Revenue. The Revenue will grow by 9.46% on average per year.
EPS Next Y13.42%
EPS Next 2Y13.06%
EPS Next 3Y13.18%
EPS Next 5Y13.75%
Revenue Next Year9.17%
Revenue Next 2Y8.88%
Revenue Next 3Y9%
Revenue Next 5Y9.46%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. IDXX Valuation Analysis
4.1 Price/Earnings Ratio
- IDXX is valuated quite expensively with a Price/Earnings ratio of 43.08.
- Compared to the rest of the industry, the Price/Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 68.62% of the companies listed in the same industry.
- IDXX is valuated expensively when we compare the Price/Earnings ratio to 26.78, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 37.98, IDXX can be considered very expensive at the moment.
- Based on the Price/Forward Earnings ratio, IDXX is valued a bit cheaper than 70.21% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 23.54. IDXX is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.08 | ||
| Fwd PE | 37.98 |
4.2 Price Multiples
- 69.15% of the companies in the same industry are more expensive than IDXX, based on the Enterprise Value to EBITDA ratio.
- IDXX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. IDXX is cheaper than 73.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.95 | ||
| EV/EBITDA | 31.11 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
- The excellent profitability rating of IDXX may justify a higher PE ratio.
- IDXX's earnings are expected to grow with 13.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.21
PEG (5Y)3.02
EPS Next 2Y13.06%
EPS Next 3Y13.18%
5. IDXX Dividend Analysis
5.1 Amount
- IDXX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IDXX Fundamentals: All Metrics, Ratios and Statistics
563
-21.75 (-3.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-02 2026-02-02/bmo
Earnings (Next)05-05 2026-05-05/bmo
Inst Owners95.6%
Inst Owner Change0%
Ins Owners0.21%
Ins Owner Change1.92%
Market Cap44.71B
Revenue(TTM)4.30B
Net Income(TTM)1.06B
Analysts80.91
Price Target761.3 (35.22%)
Short Float %2.28%
Short Ratio3.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.79%
Min EPS beat(2)3.12%
Max EPS beat(2)6.47%
EPS beat(4)4
Avg EPS beat(4)4.78%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.3%
EPS beat(12)12
Avg EPS beat(12)4.65%
EPS beat(16)14
Avg EPS beat(16)3.71%
Revenue beat(2)1
Avg Revenue beat(2)0.36%
Min Revenue beat(2)-0.31%
Max Revenue beat(2)1.03%
Revenue beat(4)2
Avg Revenue beat(4)0.17%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.74%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)3
Avg Revenue beat(16)-1.15%
PT rev (1m)0%
PT rev (3m)-1.91%
EPS NQ rev (1m)-0.22%
EPS NQ rev (3m)-0.29%
EPS NY rev (1m)0%
EPS NY rev (3m)0.23%
Revenue NQ rev (1m)0.18%
Revenue NQ rev (3m)1.42%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.08 | ||
| Fwd PE | 37.98 | ||
| P/S | 10.42 | ||
| P/FCF | 42.95 | ||
| P/OCF | 37.93 | ||
| P/B | 27.92 | ||
| P/tB | 41.45 | ||
| EV/EBITDA | 31.11 |
EPS(TTM)13.07
EY2.32%
EPS(NY)14.82
Fwd EY2.63%
FCF(TTM)13.11
FCFY2.33%
OCF(TTM)14.84
OCFY2.64%
SpS54.05
BVpS20.16
TBVpS13.58
PEG (NY)3.21
PEG (5Y)3.02
Graham Number77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.62% | ||
| ROE | 65.99% | ||
| ROCE | 61.77% | ||
| ROIC | 41.85% | ||
| ROICexc | 44.96% | ||
| ROICexgc | 57.39% | ||
| OM | 31.6% | ||
| PM (TTM) | 24.62% | ||
| GM | 61.8% | ||
| FCFM | 24.25% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.64%
ROIC(5y)38.05%
ROICexc(3y)42.76%
ROICexc(5y)42.28%
ROICexgc(3y)54.98%
ROICexgc(5y)55.56%
ROCE(3y)53.48%
ROCE(5y)55.19%
ROICexgc growth 3Y6.58%
ROICexgc growth 5Y1.33%
ROICexc growth 3Y7.31%
ROICexc growth 5Y1.49%
OM growth 3Y5.77%
OM growth 5Y4.3%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
F-Score8
Asset Turnover1.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 0.81 | ||
| Debt/EBITDA | 0.51 | ||
| Cap/Depr | 95.21% | ||
| Cap/Sales | 3.21% | ||
| Interest Coverage | 36.08 | ||
| Cash Conversion | 78.51% | ||
| Profit Quality | 98.5% | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.9 | ||
| Altman-Z | 21.39 |
F-Score8
WACC8.85%
ROIC/WACC4.73
Cap/Depr(3y)104.09%
Cap/Depr(5y)113.7%
Cap/Sales(3y)3.41%
Cap/Sales(5y)3.73%
Profit Quality(3y)93.28%
Profit Quality(5y)84.36%
High Growth Momentum
Growth
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
EPS Next Y13.42%
EPS Next 2Y13.06%
EPS Next 3Y13.18%
EPS Next 5Y13.75%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
Revenue Next Year9.17%
Revenue Next 2Y8.88%
Revenue Next 3Y9%
Revenue Next 5Y9.46%
EBIT growth 1Y20.53%
EBIT growth 3Y14.78%
EBIT growth 5Y14.44%
EBIT Next Year22.71%
EBIT Next 3Y14.82%
EBIT Next 5Y15.18%
FCF growth 1Y30.76%
FCF growth 3Y39.53%
FCF growth 5Y14.08%
OCF growth 1Y27.21%
OCF growth 3Y29.59%
OCF growth 5Y12.77%
IDEXX LABORATORIES INC / IDXX Fundamental Analysis FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
What is the valuation status for IDXX stock?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
What is the profitability of IDXX stock?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What are the PE and PB ratios of IDEXX LABORATORIES INC (IDXX) stock?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 43.08 and the Price/Book (PB) ratio is 27.92.
Can you provide the financial health for IDXX stock?
The financial health rating of IDEXX LABORATORIES INC (IDXX) is 8 / 10.